- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about SAGE
Recent news which mentions SAGE
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
From Benzinga
From Benzinga
For the 5th Time, Alta Vista Technology Appears on the Inc. 5000
August 25, 2022
From PRLog
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
August 02, 2022
From Benzinga
Earnings Scheduled For August 2, 2022
August 02, 2022
From Benzinga
Why Shares of Sage Therapeutics Climbed 15.6% This Week
June 03, 2022
From Motley Fool
1 Reason to Buy Biogen Now, and 1 Reason to Wait
May 05, 2022
From Motley Fool
From MarketWatch
From Benzinga
Earnings Scheduled For May 3, 2022
May 03, 2022
From Benzinga
Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder
May 02, 2022
From Benzinga
From Benzinga
Is This Biotech Stock Worth the Trouble?
April 23, 2022
From Motley Fool
Sage Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know
April 21, 2022
Tickers
SAGE
From Benzinga
From Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
April 03, 2022
From Benzinga
From InvestorPlace
From Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Thursday
February 17, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.